Keros Therapeutics Inc. (KROS)
NASDAQ: KROS
· Real-Time Price · USD
14.42
0.00 (0.00%)
At close: Aug 15, 2025, 2:03 PM
Keros Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| Service Revenue | 3M | 144M | 144M |
| Service Revenue Growth | -97.92% | 0.00% | n/a |
| License Revenue | 144M | n/a | n/a |
| License Revenue Growth | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 14.48M | 10.5M | 10.66M | 9.82M | 9.65M | 10.31M | 9.11M | 9.15M | 8.8M | 7.78M | 7.09M | 6.94M | 7.45M | 6.05M | 6.03M | 5.37M | 5.66M | 4.27M | 3.62M | 3.55M | 3.65M | 1.98M | 1.07M | 972K | 654K | 491K |
| Selling, General, and Administrative Revenue Growth | +37.96% | -1.58% | +8.60% | +1.71% | -6.33% | +13.21% | -0.47% | +3.92% | +13.18% | +9.66% | +2.25% | -6.85% | +23.13% | +0.25% | +12.45% | -5.18% | +32.38% | +18.16% | +1.80% | -2.66% | +84.62% | +85.29% | +9.77% | +48.62% | +33.20% | n/a |
| Research and Development Revenue | 43.5M | 48.71M | 45.63M | 49.23M | 40.52M | 38.26M | 37.49M | 34.14M | 32.53M | 31.09M | 24.87M | 21.04M | 23.28M | 18.08M | 18.83M | 14.83M | 9.98M | 11.49M | 9.67M | 8.39M | 7.26M | 8.53M | 4.16M | 3.85M | 4.5M | 4.87M |
| Research and Development Revenue Growth | -10.69% | +6.75% | -7.30% | +21.50% | +5.90% | +2.04% | +9.82% | +4.94% | +4.64% | +25.03% | +18.19% | -9.63% | +28.78% | -4.01% | +26.98% | +48.57% | -13.15% | +18.82% | +15.24% | +15.57% | -14.81% | +104.93% | +7.97% | -14.30% | -7.60% | n/a |